- Home
- NRO vs CRVS Comparison
NRO vs CRVS Comparison
Compare NRO & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRO
- CRVS
- Stock Information
- Founded
- NRO 2003
- CRVS 2014
- Country
- NRO United States
- CRVS United States
- Employees
- NRO N/A
- CRVS N/A
- Industry
- NRO Finance/Investors Services
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- NRO Finance
- CRVS Health Care
- Exchange
- NRO Nasdaq
- CRVS Nasdaq
- Market Cap
- NRO 156.7M
- CRVS 305.4M
- IPO Year
- NRO N/A
- CRVS 2016
- Fundamental
- Price
- NRO $3.25
- CRVS $3.98
- Analyst Decision
- NRO
- CRVS Strong Buy
- Analyst Count
- NRO 0
- CRVS 4
- Target Price
- NRO N/A
- CRVS $15.00
- AVG Volume (30 Days)
- NRO 239.4K
- CRVS 1.2M
- Earning Date
- NRO 01-01-0001
- CRVS 08-05-2025
- Dividend Yield
- NRO 11.41%
- CRVS N/A
- EPS Growth
- NRO N/A
- CRVS N/A
- EPS
- NRO N/A
- CRVS N/A
- Revenue
- NRO N/A
- CRVS N/A
- Revenue This Year
- NRO N/A
- CRVS N/A
- Revenue Next Year
- NRO N/A
- CRVS N/A
- P/E Ratio
- NRO N/A
- CRVS N/A
- Revenue Growth
- NRO N/A
- CRVS N/A
- 52 Week Low
- NRO $2.51
- CRVS $1.75
- 52 Week High
- NRO $3.45
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- NRO 54.87
- CRVS 50.43
- Support Level
- NRO $3.19
- CRVS $3.55
- Resistance Level
- NRO $3.27
- CRVS $4.25
- Average True Range (ATR)
- NRO 0.04
- CRVS 0.33
- MACD
- NRO 0.00
- CRVS -0.03
- Stochastic Oscillator
- NRO 79.17
- CRVS 40.19
About NRO Neuberger Berman Real Estate Securities Income Fund Inc.
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. Under normal market conditions, the Fund invests at least 90% of its total assets in income-producing common equity securities, preferred securities, convertible securities and non-convertible debt securities issued by real estate companies, including real estate investment trusts ("REITs").
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).